SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mirvie, a company bringing a personalized, predictive, and preventive approach to pregnancy complications, today announced the company was selected to present new research demonstrating the ability of the Mirvie RNA platform to predict the risk of severe fetal growth restriction in pregnancy.
The abstract, “Prediction of severely small-for-gestational-age infants using a novel cell-free RNA model,” will be presented on Thursday, January 30, 2025 9:15am MST by Dr. Kara Rood, a maternal-fetal medicine specialist and Clinical Associate Professor of Obstetrics and Gynecology at the Ohio State University Medical School, who is a principal investigator on the Miracle of Life (MoL) study.
The novel findings add to the growing body of research demonstrating the use of the Mirvie RNA platform to predict pregnancy complications months before symptoms appear, including preeclampsia risk prediction in Nature and preterm birth risk prediction in the American Journal of Obstetrics and Gynecology.
A poster presentation was also selected: “Prospective validation of USPSTF guidelines for preeclampsia prediction and clinician compliance with aspirin recommendations.” The presentation will be given by Dr. Arun Jeyabalan, MD, MSCR, Associate Professor of Obstetrics & Reproductive Services at the University of Pittsburgh and Director of the Maternal-Fetal Medicine Division at UPMC Magee-Womens Hospital. Dr. Jeyabalan is also a principal investigator of the MoL study.
The research stems from Mirvie’s foundational, first-of-its-kind study uncovering the biology of pregnancy health. This comprehensive study examined the biology of nearly 11,000 diverse pregnancies across the United States, collecting more than 20,000 RNA transcripts per patient and translating into 200 million data points overall. Mining the rich dataset with advanced machine learning and AI, Mirvie is unlocking the underlying biology of pregnancy health. The Mirvie RNA platform delivers predictive blood tests that enable preventive care across multiple pregnancy complications such as preeclampsia, preterm birth, and fetal growth restriction.
About Mirvie
Mirvie is bringing a personalized, predictive, and preventive approach to pregnancy health using RNA to predict the risk of serious complications like preeclampsia, preterm birth and fetal growth restriction, months in advance. Backed by rigorous clinical research, the proprietary Mirvie RNA platform reveals actionable information about the unique biology of a pregnancy with a simple blood test. This breakthrough allows pregnant women and their care teams to put a preventive action plan in place before a complication becomes a life-altering crisis. Serious complications impact one in five pregnancies in the U.S., and Mirvie is committed to creating a world where every pregnancy is as safe and healthy as possible. Mirvie is backed by top-tier investors including Blackrock, Decheng Capital, Foresite Capital, General Catalyst, GV, Khosla Ventures, and Mayfield.
